Literature DB >> 28090090

Incidence and prognostic impact of ASXL2 mutations in adult acute myeloid leukemia patients with t(8;21)(q22;q22): a study of the German-Austrian AML Study Group.

N Jahn1, M Agrawal1, L Bullinger1, D Weber1, A Corbacioglu1, V I Gaidzik1, L Schmalbrock1, F Thol2, M Heuser2, J Krauter3, G Göhring4, A Kündgen5, W Fiedler6, M Wattad7, G Held8, C-H Köhne9, H-A Horst10, M Lübbert11, A Ganser2, R F Schlenk1, H Döhner1, K Döhner1, P Paschka1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28090090     DOI： 10.1038/leu.2017.18

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  14 in total

1.  Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t(8;21) differ from those of patients with inv(16): a Cancer and Leukemia Group B study.

Authors:  Guido Marcucci; Krzysztof Mrózek; Amy S Ruppert; Kati Maharry; Jonathan E Kolitz; Joseph O Moore; Robert J Mayer; Mark J Pettenati; Bayard L Powell; Colin G Edwards; Lisa J Sterling; James W Vardiman; Charles A Schiffer; Andrew J Carroll; Richard A Larson; Clara D Bloomfield
Journal:  J Clin Oncol       Date:  2005-08-20       Impact factor: 44.544

2.  High number of additional genetic lesions in acute myeloid leukemia with t(8;21)/RUNX1-RUNX1T1: frequency and impact on clinical outcome.

Authors:  M-T Krauth; C Eder; T Alpermann; U Bacher; N Nadarajah; W Kern; C Haferlach; T Haferlach; S Schnittger
Journal:  Leukemia       Date:  2014-01-09       Impact factor: 11.528

3.  Acquired mutations in ASXL1 in acute myeloid leukemia: prevalence and prognostic value.

Authors:  Marta Pratcorona; Saman Abbas; Mathijs A Sanders; Jasper E Koenders; François G Kavelaars; Claudia A J Erpelinck-Verschueren; Annelieke Zeilemakers; Bob Löwenberg; Peter J M Valk
Journal:  Haematologica       Date:  2011-11-04       Impact factor: 9.941

Review 4.  Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet.

Authors:  Hartmut Döhner; Elihu H Estey; Sergio Amadori; Frederick R Appelbaum; Thomas Büchner; Alan K Burnett; Hervé Dombret; Pierre Fenaux; David Grimwade; Richard A Larson; Francesco Lo-Coco; Tomoki Naoe; Dietger Niederwieser; Gert J Ossenkoppele; Miguel A Sanz; Jorge Sierra; Martin S Tallman; Bob Löwenberg; Clara D Bloomfield
Journal:  Blood       Date:  2009-10-30       Impact factor: 22.113

5.  Individual patient data-based meta-analysis of patients aged 16 to 60 years with core binding factor acute myeloid leukemia: a survey of the German Acute Myeloid Leukemia Intergroup.

Authors:  R F Schlenk; A Benner; J Krauter; T Büchner; C Sauerland; G Ehninger; M Schaich; B Mohr; D Niederwieser; R Krahl; R Pasold; K Döhner; A Ganser; H Döhner; G Heil
Journal:  J Clin Oncol       Date:  2004-08-02       Impact factor: 44.544

6.  Expression of a conditional AML1-ETO oncogene bypasses embryonic lethality and establishes a murine model of human t(8;21) acute myeloid leukemia.

Authors:  Masakazu Higuchi; Darin O'Brien; Parasakthy Kumaravelu; Noel Lenny; Eng-Juh Yeoh; James R Downing
Journal:  Cancer Cell       Date:  2002-02       Impact factor: 31.743

Review 7.  Mutations in epigenetic modifiers in the pathogenesis and therapy of acute myeloid leukemia.

Authors:  Omar Abdel-Wahab; Ross L Levine
Journal:  Blood       Date:  2013-05-02       Impact factor: 22.113

8.  ASXL1 mutations in younger adult patients with acute myeloid leukemia: a study by the German-Austrian Acute Myeloid Leukemia Study Group.

Authors:  Peter Paschka; Richard F Schlenk; Verena I Gaidzik; Julia K Herzig; Teresa Aulitzky; Lars Bullinger; Daniela Späth; Veronika Teleanu; Andrea Kündgen; Claus-Henning Köhne; Peter Brossart; Gerhard Held; Heinz-A Horst; Mark Ringhoffer; Katharina Götze; David Nachbaur; Thomas Kindler; Michael Heuser; Felicitas Thol; Arnold Ganser; Hartmut Döhner; Konstanze Döhner
Journal:  Haematologica       Date:  2015-01-16       Impact factor: 11.047

Review 9.  Mutations in ASXL1 are associated with poor prognosis across the spectrum of malignant myeloid diseases.

Authors:  Véronique Gelsi-Boyer; Mandy Brecqueville; Raynier Devillier; Anne Murati; Marie-Joelle Mozziconacci; Daniel Birnbaum
Journal:  J Hematol Oncol       Date:  2012-03-21       Impact factor: 17.388

Review 10.  Functional and cancer genomics of ASXL family members.

Authors:  M Katoh
Journal:  Br J Cancer       Date:  2013-06-04       Impact factor: 7.640
View more
  5 in total

Review 1.  Cytotoxic therapy in acute myeloid leukemia: not quite dead yet.

Authors:  Laura C Michaelis
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2018-11-30

2.  Elevated Expression of ASXL2 is Associated with Poor Prognosis in Colorectal Cancer by Enhancing Tumorigenesis and Inducing Cell Proliferation.

Authors:  Ran Cui; Ludi Yang; Yiwei Wang; Ming Zhong; Minhao Yu; Bo Chen
Journal:  Cancer Manag Res       Date:  2020-10-19       Impact factor: 3.989

3.  Molecular characterization of AML with RUNX1-RUNX1T1 at diagnosis and relapse reveals net loss of co-mutations.

Authors:  Alexander Höllein; Niroshan Nadarajah; Manja Meggendorfer; Sabine Jeromin; Wolfgang Kern; Claudia Haferlach; Torsten Haferlach
Journal:  Hemasphere       Date:  2019-02-04

Review 4.  ASXL1/2 mutations and myeloid malignancies.

Authors:  Edward A Medina; Caroline R Delma; Feng-Chun Yang
Journal:  J Hematol Oncol       Date:  2022-09-06       Impact factor: 23.168

Review 5.  AML1/ETO and its function as a regulator of gene transcription via epigenetic mechanisms.

Authors:  Kai Rejeski; Jesús Duque-Afonso; Michael Lübbert
Journal:  Oncogene       Date:  2021-07-30       Impact factor: 9.867
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.